NeuroPace (NPCE) Other Non-Current Liabilities (2020 - 2021)

NeuroPace (NPCE) recorded quarterly Other Non-Current Liabilities of $248000.0 in Q3 2021, down 9.49% quarter-over-quarter from $274000.0 in Q1 2021.

NeuroPace (NPCE) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends

NeuroPace's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $248000.0 for Q3 2021.

In Q3 2021, Other Non-Current Liabilities changed N/A year-over-year to $248000.0; the TTM figure through Sep 2021 stood at $248000.0 (changed N/A YoY), while the FY2020 annual figure was $274000.0, changed N/A from the prior year.
Other Non-Current Liabilities was $248000.0 for Q3 2021 at NeuroPace, down from $274000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $274000.0 in Q4 2020 to a low of $248000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	NeuroPace	527.50 Mn	473.52 Mn	18.05 Mn

Download Data